/Investor DB

Blackstone Life Sciences — 2020 Investments

2 investments dated 2020 · listed companies and verified rows first · show all

Annexonannexonbio.comin𝕏Jul 2020 · $100M

Annexon is a clinical-stage biopharmaceutical company developing C1q and classical complement pathway inhibitors to treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders.

BiotechHealthtechMedical DevicesSo. San Francisco, US

Ben Barres(Scientific Co-Founder)Douglas Love(Founder)inMark L Smith(Executive Officer)Campbell Murray(Director)inThomas Wiggans(Director)Ricky Sun(Director)

Co-investorsBain Capital Life SciencesCorrelation VenturesNew Enterprise Associates (NEA)BlackRockClarus VenturesDeerfield Management Company+2 more

Imagoimagobio.comin𝕏Nov 2020 · $80Macquired by Merck

A pharmaceutical company that develops medicines and vaccines, with research pipelines and clinical trials aimed at new treatments.

BiotechHealthtech

Co-investorsFrazier Life SciencesHighlight CapitalMRL Ventures FundXeraya CapitalAmgen VenturesBlackRock+5 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.